

**SHINCORT** Injection "Yung Shin"

Shincort Injection provides a synthetic corticosteroid, structurally related to dexamethasone, with marked anti-inflammatory action. It is primarily glucocorticoid in properties, possessing minimal sodium and water retention when used in therapeutic dosage.

**INGREDIENT:**

Each mL of sterile aqueous suspension contains:  
 Triamcinolone Acetonide.....10mg

**ACTIONS:**

Naturally occurring glucocorticoids, which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

**INDICATIONS:**

Rheumatic disorders: rheumatoid arthritis, osteoarthritis, synovitis.  
 Allergic states: bronchial asthma, allergic rhinitis, allergic dermatitis.  
 Collagen diseases. Dermatologic diseases. Severe acute and chronic allergic and inflammatory ophthalmic diseases.

**DOSAGE AND ADMINISTRATION:**

Intramuscular administration.  
 For adults and children over 12 years of age, the suggested initial dose is 60 mg, injected deeply into the gluteal muscle. Dosage is usually adjusted within the range of 40 mg to 80 mg.  
 For children from 6 to 12 years of age, the suggested initial dose is 40 mg, although dosage depends more on the severity of symptoms than on age or weight.  
 For intra-articular or intrabursal administration and for injection into tendon sheaths may vary from 2.5 mg to 5 mg for smaller joints, and from 5 mg to 15 mg for larger joints depending on the specific disease entity being treated. Single injections into several joints for multiple locus involvement, up to a total of 20 mg or more, have been given without incident.  
 For intradermal administration, the initial dose of triamcinolone acetonide will vary depending upon the specific disease entity being treated but should be limited to 1.0 mg (0.1 mL) per injection site, since larger volumes are more likely to produce cutaneous atrophy.  
 Shake the vial before use to insure a uniform suspension. To be used by a physician.

**CONTRAINDICATION:**

Corticosteroids are contraindicated in patients with systemic fungal infections.

**CAUTIONS:**

1. Because it is a suspension, the preparation should not be administered intravenously. Strict aseptic technique is mandatory.
2. During prolonged therapy, a liberal protein intake is essential for counteracting the tendency to gradual weight loss sometimes associated with negative nitrogen balance, wasting and weakness of skeletal muscles.
3. Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy should be carefully observed.
4. Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. If an infection occurs during corticosteroid therapy, it should be promptly controlled by suitable antimicrobial therapy.
5. Visual disturbance: Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

**ADVERSE EFFECTS:**

Shincort has similar side effects as other corticosteroids. These side effects are normally only associated with high dose and long term therapy. The more common ones are muscular weakness, amenorrhea, hyperhidrosis, mental and neurological disturbances and masking of infections. Others include water and electrolyte imbalance which may lead to oedema, hypertension; and cardiac failure induced by water retention. Adrenal suppression, moon face, hirsutism, buffalo hump, flushing, increasing bruising, striae, acne or more seriously, Cushing's syndrome, acute pancreatitis and aseptic necrosis of bone, vision blurred.

**DRUG INTERACTION:**

Shincort interacts with the following to increase the potassium loss in the body: carbenoxolone, diuretics, bumetanide, ethacrynic acid, frusemide, piratanide, thiazides.  
 Shincort also reduces the effect of the following when given concomitantly:  
 barbiturates, carbamazepines, phenytoin, primidone, rifampicin.

**INCOMPATIBILITIES:**

Do not mix with other solutions.

**STORAGE:**

Store below 30°C and away from direct light.  
 Keep medicine away from reach of children.

**PACKAGING:**

5 mL multiple dose Vial×10 Vials.



Manufacturer:  
**YUNG SHIN PHARMACEUTICAL IND. CO., LTD.**  
 TACHIA, TAICHUNG, TAIWAN, R.O.C.  
 Imported by:  
**YUNG SHIN PHARMACEUTICAL (S) PTE. LTD.**  
 10 Ubi Crescent, #06-57/58 Ubi Techpark,  
 Singapore 408564.